title: Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol.
authors.forename: Murad
authors.initials: M
authors.lastname: Atmaca
authors.forename: Murat
authors.initials: M
authors.lastname: Kuloglu
authors.forename: Ertan
authors.initials: E
authors.lastname: Tezcan
authors.forename: Omer
authors.initials: O
authors.lastname: Gecici
authors.forename: Bilal
authors.initials: B
authors.lastname: Ustundag
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D039721:Diagnostic and Statistical Manual of Mental Disorders; D003987:Dibenzothiazepines / Q000627:therapeutic use; D005260:Female; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D020738:Leptin / Q000097:blood*; D008297:Male; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069348:Quetiapine Fumarate; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*; D014280:Triglycerides / Q000097:blood*; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D020738:Leptin; D014280:Triglycerides; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D010890:Pirenzepine; D006220:Haloperidol; D000077152:Olanzapine